China Biotech Services (08037) completed the sale of all issued share capital of Standard Pathology Laboratory and Zhuoji Healthcare

Zhitong Finance App News, China Biotechnology Service (08037) issued an announcement on matters relating to the sale of all issued share capital of Standard Pathology Laboratory Co., Ltd. and Zhuoji Healthcare Co., Ltd. All the prerequisites contained in the sale agreement have been fulfilled, and the sale was completed on August 13, 2026 in accordance with the terms and conditions of the sale agreement. Immediately after completion and on the date of this announcement, Standard Pathology Laboratory and Zhuoji Health will each cease to be a subsidiary of the Group, and the financial results of Standard Pathology Laboratory and Zhuoji Healthcare will no longer be incorporated into the Group's financial results.

The sale of the laboratory testing business is a key step in implementing the Group's strategic transformation of its business. Through the sale of the laboratory testing business in Hong Kong, which continues to lose money, the Group has been able to reallocate human, financial and operating resources to focus on the development of boron neutron capture therapy (boron neutron therapy) medical services, boron neutron therapy drugs and equipment, and strive to build a leading domestic boron neutron technology industry platform in sync with the international community.